Publications by authors named "Malin Petersson"
Article Synopsis
- A 12-week study showed that zilucoplan is effective in treating patients with generalized myasthenia gravis (gMG) who have acetylcholine receptor autoantibodies, but data beyond 12 weeks is limited.
- The study used a Bayesian model-informed analysis to predict zilucoplan's effects versus a control for up to 24 weeks, incorporating real-world and clinical trial data.
- Results showed significant improvement in the MG-ADL score for zilucoplan at 24 weeks, with a very high probability of a positive treatment effect compared to the control group.
Background And Objectives: To describe myasthenia gravis activities of daily living (MG-ADL) in relation to clinical characteristics in a large Swedish nationwide cohort.
Methods: In a cross-sectional prevalence cohort study, the Genes and Environment in Myasthenia Gravis study, performed from November 2018 through August 2019, patients with myasthenia gravis (MG) were invited to submit an extensive 106-item life environment questionnaire, including the MG-ADL score. Patients were classified into early-onset MG (EOMG, <50 years), late-onset MG (LOMG, ≥50 years), or thymoma-associated MG (TAMG).